PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.73%
R&D reduction while GNPX shows 60.19% growth. Joel Greenblatt would examine competitive risk.
3.54%
G&A growth while GNPX reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses change of 100.00% while GNPX maintains costs. Bruce Berkowitz would investigate efficiency.
-10.44%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-10.44%
Both companies reducing total costs. Martin Whitman would check industry trends.
-100.00%
Interest expense reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
721.68%
D&A growth above 1.5x GNPX's 42.70%. Michael Burry would check for excessive investment.
11.90%
EBITDA growth below 50% of GNPX's 36.78%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
10.44%
Operating income growth below 50% of GNPX's 36.96%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-34.01%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
10.28%
Pre-tax income growth below 50% of GNPX's 37.08%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.28%
Net income growth below 50% of GNPX's 37.08%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
12.12%
EPS growth below 50% of GNPX's 38.02%. Michael Burry would check for structural issues.
10.49%
Diluted EPS growth below 50% of GNPX's 38.00%. Michael Burry would check for structural issues.
2.21%
Share count reduction below 50% of GNPX's 1.59%. Michael Burry would check for concerns.
No Data
No Data available this quarter, please select a different quarter.